Get the Stockscreener App
2.74
34.61%
-1.45
After Hours:
2.75
0.010
+0.36%
Anavex Life Sciences Corporation stock is traded at $2.74, with a volume of 14.03M.
It is down -34.61% in the last 24 hours and down -37.73% over the past month.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
See More
Previous Close:
$4.19
Open:
$3.01
24h Volume:
14.03M
Relative Volume:
8.40
Market Cap:
$253.92M
Revenue:
-
Net Income/Loss:
$-39.95M
P/E Ratio:
-5.8937
EPS:
-0.4649
Net Cash Flow:
$-34.08M
1W Performance:
-35.68%
1M Performance:
-37.73%
6M Performance:
-67.76%
1Y Performance:
-71.34%
1-Day Range:
$2.61
$3.115
1-Week Range:
$2.61
$4.605
52-Week Range:
$2.61
$13.99
Anavex Life Sciences Corporation Stock (AVXL) Company Profile
Name
Anavex Life Sciences Corporation
Sector
Industry
Phone
844-689-3939
Address
630 5TH AVENUE, NEW YORK
Compare AVXL vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVXL
Anavex Life Sciences Corporation
|
2.74 | 388.29M | 0 | -39.95M | -34.08M | -0.4649 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Anavex Life Sciences Corporation Stock (AVXL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jun-23-22 | Initiated | Berenberg | Buy |
| Sep-23-21 | Initiated | BTIG Research | Buy |
| Dec-16-20 | Reiterated | H.C. Wainwright | Buy |
| Sep-28-20 | Initiated | Ladenburg Thalmann | Buy |
| Feb-27-20 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-18-19 | Initiated | Janney | Buy |
| May-16-18 | Resumed | Maxim Group | Buy |
| Mar-08-18 | Initiated | ROTH Capital | Buy |
| Feb-13-18 | Reiterated | Maxim Group | Buy |
| Sep-29-17 | Resumed | Noble Financial | Buy |
| Feb-07-17 | Initiated | Noble Financial | Buy |
| Mar-29-16 | Initiated | FBR Capital | Outperform |
View All
Anavex Life Sciences Corporation Stock (AVXL) Latest News
AVXL Plummets 31% to 52-Week Lows: A Technical Meltdown Ignites the Biotech Watchlist - Bitget
Anavex Life Sciences withdraws EU marketing application for blarcamesine after CHMP feedback - TradingView
Anavex (NASDAQ: AVXL) withdraws EU Alzheimer’s drug application for blarcamesine - Stock Titan
Crude Oil Moves Lower; Cintas Raises FY2026 Forecast - Benzinga
Dow Surges Over 300 Points; Chewy Shares Jump On Upbeat Earnings - Benzinga
Anavex Life Sciences Corp Faces Competitive Pressure Amid Financial Year Results - StocksToTrade
Anavex Life Sciences Stock Crushed As European Alzheimer's Drug Filing Pulled After EMA Pushback - Benzinga
Anavex Life Sciences Corp. (AVXL) recently disclosed the latest updates on the regulatory review of its investigational drug Blarcamesine for early Alzheimer’s disease in the European Union. - Bitget
Anavex Life Sciences stock tumbles after EU filing withdrawal By Investing.com - Investing.com UK
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease - marketscreener.com
EU review halts Anavex’s Alzheimer’s drug bid, more data next - Stock Titan
Anavex Life lead drug targets early Alzheimer's causenew study highlights - MSN
AVXL Stock Soars After Anavex’s New Data Suggests Its Alzheimer’s Drug May Slow Brain Shrinkage - Stocktwits
D. Boral Capital Reiterates Buy Rating for Anavex Life Sciences (NASDAQ:AVXL) - MarketBeat
Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease - The Manila Times
Study ties oral Alzheimer’s drug to slower brain shrinkage - Stock Titan
AVXL Technical Analysis | Trend, Signals & Chart Patterns | ANAVEX LIFE SCIENCES CORP (NASDAQ:AVXL) - ChartMill
Anavex Life Lead Drug Targets Early Alzheimer's CauseNew Study Highlights - Sahm
Form 8K Anavex Life Sciences Corp For: 9 February - Investing.com
Anavex Life Sciences Announces New Study Linking Autophagy Dysfunction to Alzheimer’s Disease Pathology - Quiver Quantitative
New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease - The Manila Times
Alzheimer’s study points to cell-cleanup failure before plaques form - Stock Titan
AVXL Stock Price, Quote & Chart | ANAVEX LIFE SCIENCES CORP (NASDAQ:AVXL) - ChartMill
Anavex Life Sciences Reports Positive Data for Blarcamesine in New Parkinson’s Disease Model at AD/PD™ 2026 Conference - Quiver Quantitative
Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference - The Manila Times
Parkinson’s therapy hope: blarcamesine regrows nerve fibers in lab model - Stock Titan
Anavex Life Sciences (NASDAQ:AVXL) Stock Price Crosses Above 50 Day Moving AverageTime to Sell? - MarketBeat
Anavex asks EMA to re-examine its negative opinion on blarcamesine for Alzheimer's - MSN
Anavex Life Sciences Stock Rises After Experimental Alzheimer’s Drug Slows Cognitive Decline In Study - MSN
AVXL SEC FilingsAnavex Life Scie 10-K, 10-Q, 8-K Forms - Stock Titan
Earnings Update: Is Anavex Life Sciences Corp a top pick in the sectorM&A Rumor & Fast Gaining Stock Reports - baoquankhu1.vn
Anavex Life Sciences Touts Oral Alzheimer’s Drug Blarcamesine Data, Cash Runway at Healthcare Conference - Yahoo Finance
Anavex Life Sciences (NASDAQ:AVXL) Stock Price Passes Above Fifty Day Moving AverageWhat's Next? - MarketBeat
What's Going On With Anavex Life Sciences Stock On Wednesday? - Benzinga
Anavex Life Sciences to Present at the Citizens Life Sciences Conference - Anavex Life Sciences
Alzheimer's-focused Anavex CEO to speak at Citizens Life Sciences Conference - Stock Titan
Anavex Life Sciences Corp. (AVXL): Investor Outlook on a Biotechnology Stock with a Potential 393% Upside - DirectorsTalk Interviews
Anavex Adds Veteran Healthcare Leader to Board of Directors - The Globe and Mail
Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference - Bitget
Anavex Life Sciences Corp. CEO to Present at TD Cowen 46th Annual Health Care Conference on March 2, 2026 - Quiver Quantitative
Alzheimer’s treatment developer Anavex to speak at TD Cowen health conference - Stock Titan
Anavex Life Sciences (NASDAQ:AVXL) Shares Cross Below 50-Day Moving AverageHere's What Happened - MarketBeat
EBITDA per share of Anavex Life Sciences Corp. – LSE:0HFR - TradingView
Anavex Life Sciences appoints Dr. Axel Paeger to board By Investing.com - Investing.com India
Anavex Life Sciences appoints Dr. Axel Paeger to board - Investing.com
Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors - marketscreener.com
Anavex Life Sciences Corp. (AVXL) Stock Analysis: Unveiling a Remarkable 433.98% Potential Upside - DirectorsTalk Interviews
Why analysts upgrade Anavex Life Sciences Corp. stockAnalyst Upgrade & AI Powered Buy/Sell Recommendations - mfd.ru
Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update - Anavex Life Sciences
Anavex Life Sciences (NASDAQ:AVXL) Upgraded at Wall Street Zen - MarketBeat
Anavex Life Sciences Corporation Stock (AVXL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):